Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cerevel Therapeutics Corporate Presentation

11/10/2021 | 06:47am EST

Transforming the Possible in Neuroscience

3Q 2021 Financial Results & Business Update

November 2021

Forward-Looking Statements

This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward- looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.

Forward-looking statements in this presentation include, but are not limited to: statements about the potential attributes and benefits of our product candidates, including with respect to receptor subtype selectivity, activity, side effect and tolerability profile and relevant indications; the format and timing of our product development activities and clinical trials, including the advancement of CVL-231 into a comprehensive Phase 2 program in schizophrenia, plans to evaluate the potential of this mechanism in other populations, including dementia-related psychosis, the presentation of additional CVL-231 PK/PD data at ACNP, the timing and status of our Phase 1 trial of darigabat in acute anxiety and other statements regarding the design of clinical trials and the timing of initiation, completion and data readouts for clinical trials; the timing and outcome of IND submissions and other regulatory interactions; the ability to compete with other companies currently marketing or engaged in the development of treatments for relevant indications; the size and growth potential of the markets for product candidates and ability to serve those markets; the rate and degree of market acceptance of product candidates, if approved; the amount and timing of payments we may receive pursuant to the tavapadon financing transaction; the sufficiency of our financial resources and our cash runway.

We cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that we may not realize the expected benefits of the financing transaction; that clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including

those under the heading "Risk Factors" in our Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 and our subsequent SEC filings.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

© Cerevel Therapeutics Holdings, Inc.

2

Agenda

Introduction

Overview

Matthew Calistri

Vice President, Corporate Strategy and Investor Relations

Tony Coles, M.D.

Chairperson & Chief Executive Officer

Lead Program Updates

Raymond Sanchez, M.D.

Chief Medical Officer

Early Pipeline Updates

John Renger, Ph.D.

Chief Scientific Officer

Q3 Financial Performance

Mark Bodenrader

Interim Chief Financial Officer

Q&A

All

© Cerevel Therapeutics Holdings, Inc.

3

Business & Pipeline Updates

Pipeline

  • Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022
  • Additional PK/PD CVL-231data to be presented at American College of Neuropsychopharmacology (ACNP) in December 2021

Capital

Cash balance of $670 million as of 9/30/2021

Cash runway projected into 2024

© Cerevel Therapeutics Holdings, Inc.

4

Company Highlights

Pursuing a targeted approach to neuroscience that combines a differentiated

CNSunderstandingdiseases

of neurocircuitry with advanced chemistry to develop novel therapies for

  • Broad portfolio of 11 assets targeting large markets with significant unmet need, including schizophrenia, epilepsy and Parkinson's Disease
  • Progressing towards multiple near and medium-term catalysts, with at least 7 data readouts and multiple INDs expected by the end of 2023
  • Leveraging a seasoned management team with extensive expertise in neuroscience and a strong track record of over 20 prior drug approvals and commercialization

© Cerevel Therapeutics Holdings, Inc.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Cerevel Therapeutics Holdings Inc. published this content on 10 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2021 11:46:08 UTC.


ę Publicnow 2021
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
01/10CEREVEL THERAPEUTICS TO PRESENT AT 4 : Additional Details of Phase 2 Program for Emraclidi..
AQ
01/05JPMorgan Starts Cerevel Therapeutics Holdings at Overweight With $50 Price Target
MT
01/03Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021Cerevel Agrees Multi-year Collaboration With Herophilus to Research, Develop Therapeuti..
MT
2021HC Wainwright Starts Cerevel Therapeutics Holdings at Buy With $50 Price Target
MT
2021CVL-231 : Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia
PU
2021CEREVEL THERAPEUTICS : Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 in Nonhum..
PU
2021Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates ..
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -221 M - -
Net cash 2021 609 M - -
P/E ratio 2021 -15,8x
Yield 2021 -
Capitalization 3 753 M 3 753 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 168
Free-Float -
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 25,49 $
Average target price 47,80 $
Spread / Average Target 87,5%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-21.13%3 765
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-12.11%50 700
BIONTECH SE-39.30%37 796